InspireMD/$NSPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About InspireMD
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Ticker
$NSPR
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
66
ISIN
US45779A8466
Website
InspireMD Metrics
BasicAdvanced
$72M
-
-$0.79
0.61
-
Price and volume
Market cap
$72M
Beta
0.61
52-week high
$3.80
52-week low
$1.99
Average daily volume
273K
Financial strength
Current ratio
4.363
Quick ratio
3.859
Long term debt to equity
5.782
Total debt to equity
8.192
Profitability
EBITDA (TTM)
-37.24
Gross margin (TTM)
21.43%
Net profit margin (TTM)
-514.29%
Operating margin (TTM)
-534.35%
Effective tax rate (TTM)
-0.16%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-58.16%
Return on equity (TTM)
-113.95%
Valuation
Price to revenue (TTM)
15.339
Price to book
2.47
Price to tangible book (TTM)
2.47
Price to free cash flow (TTM)
-3.968
Free cash flow yield (TTM)
-25.20%
Free cash flow per share (TTM)
-59.22%
Growth
Revenue change (TTM)
8.49%
Earnings per share change (TTM)
6.97%
3-year revenue growth (CAGR)
14.57%
10-year revenue growth (CAGR)
14.51%
3-year earnings per share growth (CAGR)
-27.65%
What the Analysts think about InspireMD
Analyst ratings (Buy, Hold, Sell) for InspireMD stock.
InspireMD Financial Performance
Revenues and expenses
InspireMD Earnings Performance
Company profitability
InspireMD News
AllArticlesVideos
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
GlobeNewsWire·6 days ago
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke
GlobeNewsWire·3 weeks ago
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for InspireMD stock?
InspireMD (NSPR) has a market cap of $72M as of July 15, 2025.
What is the P/E ratio for InspireMD stock?
The price to earnings (P/E) ratio for InspireMD (NSPR) stock is 0 as of July 15, 2025.
Does InspireMD stock pay dividends?
No, InspireMD (NSPR) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next InspireMD dividend payment date?
InspireMD (NSPR) stock does not pay dividends to its shareholders.
What is the beta indicator for InspireMD?
InspireMD (NSPR) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.